Navidea Biopharmaceuticals, Inc.

Equities

NAVB

US63937X2027

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:29:06 2024-05-10 pm EDT			5-day change	1st Jan Change
0.036 ^USD	-5.26%		-6.01%	-34.78%

2023	Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding	CI
2023	Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Navidea Biopharmaceuticals, Inc. Announces Resignation of Michael Rosol as Chief Medical Officer, Effective April 10, 2023

March 30, 2023 at 05:02 pm EDT

Navidea Biopharmaceuticals, Inc. announced Michael Rosol, Ph.D., has stepped down as Chief Medical Officer for the Company, with effect from April 10, 2023. After serving as Chief Medical Officer for the Navidea since 2018, Michael Rosol, Ph.D., has decided to step down to pursue opportunities outside the organization. The role of Chief Medical Officer will be assumed by existing leadership with coordinated support from G2G Ventures.

Further, Dr. Rosol will provide transition consulting services to the Company to continue to support its progress and growth.

Latest news about Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding	Nov. 26	CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Navidea Biopharmaceuticals, Inc.(OTCPK:NAVB) dropped from S&P TMI Index	23-10-11	CI
Sector Update: Health Care	23-10-06	MT
Top Midday Decliners	23-10-06	MT
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision	23-10-06	MT
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board	23-08-08	CI
Navidea Biopharmaceuticals, Inc. Announces Executive Changes	23-07-28	CI
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer	23-07-27	CI
Navidea Biopharmaceuticals, Inc. Announces Board Changes	23-07-13	CI
Navidea Biopharmaceuticals Confirms Rejection of ProPhase Labs' Proposal to Buy Some of Its Assets	23-06-30	MT
ProPhase Labs Says Offer to Acquire Certain Navidea Biopharmaceuticals' Assets Rejected	23-06-29	MT
ProPhase Labs, Inc. cancelled the acquisition of Certain Assets from Navidea Biopharmaceuticals, Inc. for $7 million.	23-06-28	CI
Sector Update: Health Care Stocks Steady Late Friday	23-06-16	MT
Sector Update: Health Care	23-06-16	MT
Navidea Biopharmaceuticals Gets $7.5 Million Payment From Cardinal Health	23-06-16	MT
Navidea Biopharmaceuticals Notified of Non-Compliance With NYSE American Listing Rule	23-06-05	MT
Navidea Biopharmaceuticals, Inc. Announces Board Changes	23-06-01	CI
Navidea Biopharmaceuticals Sells Preferred Shares Worth $1.1 Million	23-05-23	MT
Navidea Biopharmaceuticals, Inc. announced that it expects to receive $1.1 million in funding	23-05-21	CI
Navidea Biopharmaceuticals Promotes Michael Sherman Blue to Chief Medical Officer	23-05-11	MT
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer	23-05-11	CI
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Navidea Biopharmaceuticals Intends to Sell Cardinal Milestone Payment	23-04-27	CI

Chart Navidea Biopharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Companyâs business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NAVIDEA BIOPHARMACEUTICALS, INC.	-34.78%	3.6M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research